These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 25137409)

  • 1. Maternal plasma DNA testing: experience of women counseled at a prenatal diagnosis center.
    O'Brien BM; Kloza EM; Halliday JV; Lambert-Messerlian GM; Palomaki GE
    Genet Test Mol Biomarkers; 2014 Oct; 18(10):665-9. PubMed ID: 25137409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of detection of cell-free fetal DNA in maternal plasma in the prenatal diagnosis of chromosomal abnormalities].
    Wang SJ; Gao ZY; Lu YP; Li YL; You YQ; Zhang LW; Wang LX; Xu H
    Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):808-12. PubMed ID: 23302119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient acceptance of non-invasive testing for fetal aneuploidy via cell-free fetal DNA.
    Vahanian SA; Baraa Allaf M; Yeh C; Chavez MR; Kinzler WL; Vintzileos AM
    J Matern Fetal Neonatal Med; 2014 Jan; 27(1):106-9. PubMed ID: 23687914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive prenatal testing: impact on genetic counseling, invasive prenatal diagnosis, and trisomy 21 detection.
    Wax JR; Cartin A; Chard R; Lucas FL; Pinette MG
    J Clin Ultrasound; 2015 Jan; 43(1):1-6. PubMed ID: 25303161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening.
    Chetty S; Garabedian MJ; Norton ME
    Prenat Diagn; 2013 Jun; 33(6):542-6. PubMed ID: 23592525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of first-trimester screening on AMA patients' uptake of invasive testing.
    Wray AM; Ghidini A; Alvis C; Hodor J; Landy HJ; Poggi SH
    Prenat Diagn; 2005 May; 25(5):350-3. PubMed ID: 15906421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationwide demonstration project of next-generation sequencing of cell-free DNA in maternal plasma in Japan: 1-year experience.
    Sago H; Sekizawa A;
    Prenat Diagn; 2015 Apr; 35(4):331-6. PubMed ID: 25408438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of invasive prenatal diagnostic tests in women after detection of soft markers for chromosomal abnormality on ultrasonographic evaluation.
    Sharda S; Phadke SR
    J Perinatol; 2007 Sep; 27(9):550-5. PubMed ID: 17611609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy.
    American College of Obstetricians and Gynecologists Committee on Genetics
    Obstet Gynecol; 2012 Dec; 120(6):1532-4. PubMed ID: 23168792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical application of noninvasive prenatal diagnosis using cell free fetal DNA in maternal plasma].
    Hou QF; Wu D; Chu Y; Kang B; Liao SX; Yang YL; Zhang CY; Zhang JX; Wu G
    Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):813-7. PubMed ID: 23302120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of noninvasive prenatal testing on the practice of maternal-fetal medicine.
    Friel LA; Czerwinski JL; Singletary CN
    Am J Perinatol; 2014 Oct; 31(9):759-64. PubMed ID: 24338115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non invasive prenatal test (NIPT) in maternal blood by parallel massive sequencing. Initial experience in Mexican women and literature review].
    Hernández-Gómez M; Ramirez-Arroyo E; Meléndez-Hernández R; Garduño-Zaraza LM; Mayén-Molina DG
    Ginecol Obstet Mex; 2015 May; 83(5):277-88. PubMed ID: 26233973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis.
    Beulen L; Grutters JP; Faas BH; Feenstra I; van Vugt JM; Bekker MN
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():53-61. PubMed ID: 25238658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMFM Statement: clarification of recommendations regarding cell-free DNA aneuploidy screening.
    Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: esteele@smfm.org
    Am J Obstet Gynecol; 2015 Dec; 213(6):753-4. PubMed ID: 26458766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the introduction of the national Down syndrome screening program in the Netherlands: age-related uptake of prenatal screening and invasive diagnostic testing.
    Engels MA; Bhola SL; Twisk JW; Blankenstein MA; van Vugt JM
    Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():59-63. PubMed ID: 24405726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for trisomies 21, 18 and 13 by cell-free DNA analysis of maternal blood at 10-11 weeks' gestation and the combined test at 11-13 weeks.
    Quezada MS; Gil MM; Francisco C; Oròsz G; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):36-41. PubMed ID: 25251385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. People who influence women's decisions and preferred sources of information about prenatal testing for birth defects.
    Jaques AM; Bell RJ; Watson L; Halliday JL
    Aust N Z J Obstet Gynaecol; 2004 Jun; 44(3):233-8. PubMed ID: 15191448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies.
    O'Leary P; Maxwell S; Murch A; Hendrie D
    Aust N Z J Obstet Gynaecol; 2013 Oct; 53(5):425-33. PubMed ID: 24090461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective evaluation of maternal serum screening for the detection of fetal aneuploidy.
    Suzumori K; Tanemura M; Murakami I; Okada S; Natori M; Tanaka M; Takagi T; Sato A
    Prenat Diagn; 1997 Sep; 17(9):861-6. PubMed ID: 9316131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliable noninvasive prenatal testing by massively parallel sequencing of circulating cell-free DNA from maternal plasma processed up to 24h after venipuncture.
    Buysse K; Beulen L; Gomes I; Gilissen C; Keesmaat C; Janssen IM; Derks-Willemen JJ; de Ligt J; Feenstra I; Bekker MN; van Vugt JM; Geurts van Kessel A; Vissers LE; Faas BH
    Clin Biochem; 2013 Dec; 46(18):1783-6. PubMed ID: 23933476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.